Try our Advanced Search for more refined results

VISTA HEALTHPLAN, INC. v. CEPHALON, INC. et al

  1. August 09, 2019

    Court OKs $65.8M Deal In Cephalon Pay-For-Delay Suit

    A Pennsylvania federal judge has given an early green light to a total of $65.8 million in settlements to end class action claims that Cephalon paid generic-drug makers to keep a cheaper version of the narcolepsy drug Provigil away from drug counters.

  2. March 26, 2019

    Cephalon, Mylan, Ranbaxy Ink Combined $65.8M Provigil Deal

    Proposed consumer classes have reached a $65.8 million deal in a suit claiming Mylan and Ranbaxy participated in pay-for-delay deals with Cephalon to prevent the sale of generic versions of the narcolepsy drug Provigil, they told a Pennsylvania federal court Tuesday.

  3. January 26, 2016

    3rd Circ. Stays Provigil Pay-For-Delay Trial During Cert. Appeal

    The Third Circuit agreed Monday to stay an upcoming trial in a class action accusing Mylan and Ranbaxy Laboratories of inking pay-for-delay deals with Cephalon to keep generic versions of narcolepsy drug Provigil off the market while the appeals court weighs the decision to certify the class.

  4. January 22, 2016

    Drug Buyers Must Play Nice At Trial, Provigil Judge Says

    Days before drugmakers including Cephalon Inc. are set to face a jury over an alleged pay-for-delay scheme involving its sleep-disorder medicine Provigil, a Pennsylvania federal judge has ruled the group suing isn't allowed to use certain prejudicial terms, bring up past guilty pleas or discuss pharmaceutical industry policies.

  5. January 14, 2016

    No Need To Split Provigil Claims Before Trial, Cephalon Says

    Cephalon Inc. resisted efforts Wednesday to separate certain Apotex claims from an upcoming trial in the pay-for-delay litigation over sleep-disorder medicine Provigil, telling a Pennsylvania federal judge it would unnecessarily complicate the case.

  6. January 04, 2016

    Provigil Antitrust Trial Should Be Postponed, Drug Cos. Say

    Mylan and Ranbaxy Laboratories doubled down Monday on their request that the Third Circuit pause an upcoming pay-for-delay trial over Cephalon Inc.'s narcolepsy drug Provigil while the appeals court hears their challenge to class certification, saying such a stay is necessary.

  7. December 22, 2015

    Drug Cos. Ask 3rd Circ. To Halt Trial For Class Cert. Fight

    Mylan Inc. and Ranbaxy Laboratories Inc. have urged the Third Circuit to halt an upcoming pay-for-delay trial over Cephalon Inc.'s narcolepsy drug Provigil while the appeals court hears their challenge to class certification, arguing Monday that the district court doesn't have jurisdiction over the case while the original appeal is pending.

  8. December 17, 2015

    Mylan, Ranbaxy Can't Halt Pay-For-Delay Suits Pending Appeal

    A Pennsylvania federal judge on Thursday refused to pause pay-for-delay litigation against Mylan Inc. and Ranbaxy Laboratories Inc. over Cephalon Inc.'s narcolepsy drug Provigil while the Third Circuit hears the drug companies' appeal of a class certification order.

  9. November 20, 2015

    Mylan, Ranbaxy Urge Stay Of Provigil Pay-For-Delay Suits

    Mylan Inc. and Ranbaxy Laboratories Ltd. on Thursday urged a Pennsylvania federal judge to stay three cases accusing them and others of accepting $300 million from Cephalon Inc. to delay generic versions of its narcolepsy drug Provigil, pending their effort to overturn a class certification order in the Third Circuit.

  10. August 05, 2015

    Pa. Judge Won't Rethink Denial Of Provigil Buyers' Class Cert.

    A Pennsylvania federal judge on Tuesday swatted away a bid by consumers and health plans who filed pay-for-delay litigation over Cephalon Inc.'s narcolepsy drug Provigil to reconsider a decision not to certify them as a class, rejecting their contention that the court made several key errors.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!